ArticleNature communications2023

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer.

Bhavana Palakurthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.